SK286267B6 - Kryštalické formy 1S-[1alfa(2S*, 3R*), 9alfa]-6,10-dioxo-N-(2- etoxy-5-oxotetrahydro-3-furanyl)-9-[[(1-izochinolyl)karbonyl]- amino]-oktahydro-6H-pyridazino[1,2-a][1,2]diazepín-1-karboxamidu, spôsob ich výroby a použitie a farmaceutické kompozície sich obsahom - Google Patents

Kryštalické formy 1S-[1alfa(2S*, 3R*), 9alfa]-6,10-dioxo-N-(2- etoxy-5-oxotetrahydro-3-furanyl)-9-[[(1-izochinolyl)karbonyl]- amino]-oktahydro-6H-pyridazino[1,2-a][1,2]diazepín-1-karboxamidu, spôsob ich výroby a použitie a farmaceutické kompozície sich obsahom Download PDF

Info

Publication number
SK286267B6
SK286267B6 SK1488-2000A SK14882000A SK286267B6 SK 286267 B6 SK286267 B6 SK 286267B6 SK 14882000 A SK14882000 A SK 14882000A SK 286267 B6 SK286267 B6 SK 286267B6
Authority
SK
Slovakia
Prior art keywords
crystalline form
octahydro
furanyl
ethoxy
carbonyl
Prior art date
Application number
SK1488-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK14882000A3 (sk
Inventor
Jean-Yves Godard
Val�Rie Rognon
Original Assignee
Aventis Pharma S. A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S. A. filed Critical Aventis Pharma S. A.
Publication of SK14882000A3 publication Critical patent/SK14882000A3/sk
Publication of SK286267B6 publication Critical patent/SK286267B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
SK1488-2000A 1998-04-08 1999-04-07 Kryštalické formy 1S-[1alfa(2S*, 3R*), 9alfa]-6,10-dioxo-N-(2- etoxy-5-oxotetrahydro-3-furanyl)-9-[[(1-izochinolyl)karbonyl]- amino]-oktahydro-6H-pyridazino[1,2-a][1,2]diazepín-1-karboxamidu, spôsob ich výroby a použitie a farmaceutické kompozície sich obsahom SK286267B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9804367A FR2777279B1 (fr) 1998-04-08 1998-04-08 Nouvelles formes cristallines du 1s-[1alpha(2s*,3r*), 9 alpha] 6,10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl) -9[[(1-isoquinolyl)carbonyl]amino]octohydro-6h-pyridazino [1,2-a][1,2]diazepine-1-carboxamide
PCT/FR1999/000799 WO1999052935A1 (fr) 1998-04-08 1999-04-07 Formes cristallines du 1s-[1alpha (2s*,3r*),9alpha]-6, 10-dioxo-n- (2-ethoxy-5 -oxo-tetrahydro-3 -furanyl) -9-[[(1-isoquinolyl) carbonyl]-amino] octahydro-6h -piridazino[1, 2-a][1,2] diazepine-1- carboxamide

Publications (2)

Publication Number Publication Date
SK14882000A3 SK14882000A3 (sk) 2001-04-09
SK286267B6 true SK286267B6 (sk) 2008-06-06

Family

ID=9524993

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1488-2000A SK286267B6 (sk) 1998-04-08 1999-04-07 Kryštalické formy 1S-[1alfa(2S*, 3R*), 9alfa]-6,10-dioxo-N-(2- etoxy-5-oxotetrahydro-3-furanyl)-9-[[(1-izochinolyl)karbonyl]- amino]-oktahydro-6H-pyridazino[1,2-a][1,2]diazepín-1-karboxamidu, spôsob ich výroby a použitie a farmaceutické kompozície sich obsahom

Country Status (38)

Country Link
US (2) US6544977B1 (zh)
EP (1) EP1070083B1 (zh)
JP (1) JP2002511485A (zh)
KR (1) KR100582981B1 (zh)
CN (1) CN1202123C (zh)
AP (1) AP1734A (zh)
AR (1) AR018328A1 (zh)
AT (1) ATE315044T1 (zh)
AU (1) AU758042B2 (zh)
BG (1) BG64736B1 (zh)
BR (1) BR9909549A (zh)
CA (1) CA2325629C (zh)
CU (1) CU23055A3 (zh)
CZ (1) CZ299744B6 (zh)
DE (1) DE69929315T2 (zh)
DK (1) DK1070083T3 (zh)
EA (1) EA002761B1 (zh)
EE (1) EE04467B1 (zh)
ES (1) ES2253880T3 (zh)
FR (1) FR2777279B1 (zh)
GE (1) GEP20032974B (zh)
HK (1) HK1038575B (zh)
HR (1) HRP20000665B1 (zh)
HU (1) HU227561B1 (zh)
ID (1) ID26290A (zh)
IL (2) IL138818A (zh)
ME (1) ME01627B (zh)
NO (1) NO327995B1 (zh)
NZ (1) NZ507199A (zh)
PL (1) PL197016B1 (zh)
RS (1) RS49916B (zh)
SI (1) SI1070083T1 (zh)
SK (1) SK286267B6 (zh)
TR (1) TR200002914T2 (zh)
TW (1) TW522152B (zh)
UA (1) UA71563C2 (zh)
WO (1) WO1999052935A1 (zh)
ZA (1) ZA200005438B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101479245B (zh) * 2006-06-30 2013-05-22 诺瓦提斯公司 喹啉酮衍生物和其药物组合物
AU2014277867B2 (en) * 2007-12-04 2016-11-03 Arbutus Biopharma Corporation Targeting lipids

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5552400A (en) * 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors

Also Published As

Publication number Publication date
DK1070083T3 (da) 2006-05-15
AR018328A1 (es) 2001-11-14
CZ299744B6 (cs) 2008-11-12
EE04467B1 (et) 2005-04-15
FR2777279B1 (fr) 2004-08-13
CA2325629C (fr) 2013-01-22
CU23055A3 (es) 2005-06-24
ATE315044T1 (de) 2006-02-15
SK14882000A3 (sk) 2001-04-09
SI1070083T1 (sl) 2006-04-30
CN1305491A (zh) 2001-07-25
CA2325629A1 (fr) 1999-10-21
AU3041699A (en) 1999-11-01
NO20005060L (no) 2000-10-06
JP2002511485A (ja) 2002-04-16
ID26290A (id) 2000-12-14
YU60800A (sh) 2002-11-15
HU227561B1 (en) 2011-08-29
IL168047A (en) 2011-10-31
NO327995B1 (no) 2009-11-02
EE200000586A (et) 2002-02-15
EA200001047A1 (ru) 2001-04-23
HUP0101586A3 (en) 2002-11-28
HRP20000665A2 (en) 2001-08-31
AP2000001939A0 (en) 2000-12-31
FR2777279A1 (fr) 1999-10-15
CZ20003678A3 (cs) 2001-02-14
DE69929315T2 (de) 2006-08-17
NO20005060D0 (no) 2000-10-06
DE69929315D1 (de) 2006-03-30
RS49916B (sr) 2008-09-29
AU758042B2 (en) 2003-03-13
EA002761B1 (ru) 2002-08-29
KR20010034759A (ko) 2001-04-25
GEP20032974B (en) 2003-05-27
AP1734A (en) 2007-03-22
UA71563C2 (uk) 2004-12-15
US20030171365A1 (en) 2003-09-11
US6544977B1 (en) 2003-04-08
BR9909549A (pt) 2000-12-12
BG64736B1 (bg) 2006-01-31
HRP20000665B1 (en) 2008-01-31
HUP0101586A2 (hu) 2001-11-28
WO1999052935A1 (fr) 1999-10-21
PL343350A1 (en) 2001-08-13
HK1038575B (zh) 2006-01-06
ME01627B (me) 2008-09-29
EP1070083A1 (fr) 2001-01-24
BG104829A (en) 2001-05-31
ZA200005438B (en) 2002-01-07
US6946459B2 (en) 2005-09-20
KR100582981B1 (ko) 2006-05-24
ES2253880T3 (es) 2006-06-01
TW522152B (en) 2003-03-01
TR200002914T2 (tr) 2001-02-21
NZ507199A (en) 2002-12-20
PL197016B1 (pl) 2008-02-29
HK1038575A1 (en) 2002-03-22
CN1202123C (zh) 2005-05-18
IL138818A (en) 2008-11-26
EP1070083B1 (fr) 2006-01-04

Similar Documents

Publication Publication Date Title
CN102985423B (zh) 嘌呤衍生物的结晶形式
CA2807082C (en) Crystalline form of pyrimido[6,1-a]isoquinolin-4-one compound
ZA200402999B (en) Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same.
AU1641592A (en) Crystalline tiagabine hydrochloride monohydrate, its preparation and use
SK286267B6 (sk) Kryštalické formy 1S-[1alfa(2S*, 3R*), 9alfa]-6,10-dioxo-N-(2- etoxy-5-oxotetrahydro-3-furanyl)-9-[[(1-izochinolyl)karbonyl]- amino]-oktahydro-6H-pyridazino[1,2-a][1,2]diazepín-1-karboxamidu, spôsob ich výroby a použitie a farmaceutické kompozície sich obsahom
US9593117B2 (en) Crystalline form of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
JP3317649B2 (ja) 結晶形態のカルバペネム化合物
SK283735B6 (sk) Forma VI 5,6-dichlór-2-(izopropylamino)-1-(beta-L-ribofuranozyl)- 1H-benzimidazolu, spôsob jej prípravy, farmaceutický prostriedok s jej obsahom a jej použitie
US9464086B2 (en) Crystalline forms of N,N-dicyclopropyl-4-(1,5-dimethyl-1 H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
DE602004010837T2 (de) Pharmazeutische zusammensetzung auf basis eines idazoxan-salzes oder eines seiner polymorphen
EP1813602A1 (en) Crystal of two-ring heterocyclic sulfonamide compound
SK17342001A3 (sk) Polymorfné formy kryštalického (2-benzhydryl-1-azabicyklo- [2.2.2]okt-3-yl)-(5-izopropyl-2-metoxybenzyl)amín-citrátu ako antagonistov receptora NK-1
MXPA00009662A (en) Crystalline forms of 1s-[1alpha (2s*,3r*), 9alpha]-6, 10-dioxo-n- (2-ethoxy-5 -oxo-tetrahydro-3 -furanyl) -9-[[(1-isoquinolyl) carbonyl]-amino]octahydro-6h -piridazino[1, 2-a][1,2]diazepin- 1-carboxamide
KR20070007766A (ko) 3-베타-아미노 17-메틸렌 안드로스테인-6-알파 7-베타-디올하이드로클로라이드의 결정질 형태

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20180407